Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,749 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.
Nonomiya Y, Yokokawa T, Kawakami K, Kobayashi K, Aoyama T, Takiguchi T, Sugisaki T, Suzuki K, Suenaga M, Wakatsuki T, Yamaguchi K, Sugimoto Y, Hama T. Nonomiya Y, et al. Among authors: yamaguchi k. Oncol Res. 2019 May 7;27(5):551-556. doi: 10.3727/096504018X15291727589740. Epub 2018 Jun 18. Oncol Res. 2019. PMID: 29914591 Free PMC article.
Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: results of a prospective multicenter registry.
Satoh T, Gemma A, Kudoh S, Sakai F, Yamaguchi K, Watanabe T, Ishiguro M, Inoshiri S, Izawa M, Sugihara K, Sakata Y. Satoh T, et al. Among authors: yamaguchi k. Jpn J Clin Oncol. 2014 Nov;44(11):1032-9. doi: 10.1093/jjco/hyu128. Epub 2014 Sep 10. Jpn J Clin Oncol. 2014. PMID: 25210144 Free PMC article.
Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.
Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, Dan S, Shinozaki E, Seimiya H, Mizunuma N, Yamaguchi K, Yamaguchi T. Suenaga M, et al. Among authors: yamaguchi t, yamaguchi k. Oncotarget. 2016 Jun 7;7(23):34811-23. doi: 10.18632/oncotarget.9187. Oncotarget. 2016. PMID: 27166185 Free PMC article.
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I, Shinozaki E, Matsushima T, Wakatsuki T, Ogura M, Ichimura T, Ozaka M, Takahari D, Suenaga M, Chin K, Mizunuma N, Yamaguchi K. Nakayama I, et al. Among authors: yamaguchi k. BMC Cancer. 2017 Jan 9;17(1):38. doi: 10.1186/s12885-016-2994-6. BMC Cancer. 2017. PMID: 28068936 Free PMC article.
Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer.
Osumi H, Shinozaki E, Suenaga M, Wakatsuki T, Nakayama I, Matsushima T, Ogura M, Ichimura T, Takahari D, Chin K, Nagasaki T, Konishi T, Akiyoshi T, Fujimoto Y, Nagayama S, Fukunaga Y, Ueno M, Yamaguchi K. Osumi H, et al. Among authors: yamaguchi k. PLoS One. 2017 May 31;12(5):e0176745. doi: 10.1371/journal.pone.0176745. eCollection 2017. PLoS One. 2017. PMID: 28562679 Free PMC article.
7,749 results